Messelink, Marianne A.
van der Leeuw, Matthijs S.
den Broeder, Alfons A.
Tekstra, Janneke
van der Goes, Marlies C.
Heijstek, Marloes W.
Lafeber, Floris
Welsing, Paco M. J.
Funding for this research was provided by:
ZonMw (848018009)
Article History
Received: 3 December 2021
Accepted: 9 June 2022
First Online: 16 June 2022
Declarations
:
: This study has been approved by the independent Ethical Committee of the UMC Utrecht (protocol number NL74537.041.20). Written informed consent will be provided by each participant before the start of study assessments or the intervention.
: The patient data that will be published is stated in the informed consent. The Dutch consent form for this trial is available upon request.
: AB: grants to institution from Lilly, Abbvie, Galapagos, Novartis, Gilead, Pfizer. Rituximab related patent pending. Speakers fees (indirectly) from Abbvie, Galapagos.No other competing interests to declare.